Featured Publications
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.Peer-Reviewed Original Research
2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 652-656. PMID: 18178624, PMCID: PMC2206591, DOI: 10.1073/pnas.0708594105.Peer-Reviewed Original ResearchConceptsCancer immunoeditingWT controlsAdaptor myeloid differentiation factor 88Myeloid differentiation factor 88Adaptive immune surveillanceMyD88-/- miceMyD88-deficient miceRole of TNFDMBA/TPAInflammation-induced cancerDistinct mouse modelsTNF-deficient miceInflammation-induced carcinogenesisO-tetradecanoylphorbol 13Mouse tumor modelsFactor 88WT miceChronic inflammationMCA sarcomaProinflammatory processesTumor immunologistsImmune surveillanceMouse modelSkin papillomasPrimary tumorigenesis